In chronic myelogenous leukemia and in a subset of acute lymphoblastic leukemias, the c-abl proto-oncogene undergoes a (9;22) chromosomal translocation producing a novel rearranged chromosome (the Philadelphia chromosome) as the result of the fusion of c-Abl sequences from chromosome 9 to the Bcr gene on chromosome 22. The molecular consequence of this translocation is the generation of a chimeric Bcr/Abl mRNA encoding activated Abl protein tyrosine kinase. It has been implicated in regulation of cell proliferation, differentiation, apoptosis, cell adhesion and stress response (1-3). c-Abl kinase activity is increased in vivo by diverse physiological stimuli including integrin activation, PDGF stimulation and binding to c-Jun, Nck and RFX1.

Suitable for use in ELISA, Western Blot, Immunoprecipitation and Immunofluoroescence. Other applications not tested.

Western Blot: 1:1000, incubate membrane with diluted antibody in 5% BSA, 1X TBS, 0.1% Tween-20 at 4°C with gentle shaking, overnight. Recognizes bands at 135kD (c-Abl) (210kD (Bcr-Abl)). Immunoprecipitation: 1:100 Immunofluorescence: 1:25 Optimal dilutions to be determined by the researcher.

May be stored at 4°C for short-term only. For long-term storage, store at -20°C. Aliquots are stable for at least 12 months at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.

Synthetic peptide derived from the C-terminus of human c-Abl.

Supplied as a liquid in 10mM HEPES, pH 7.5, 150mM sodium chloride, 0.1mg/ml BSA, 50% glycerol. No preservative added.

Purified by Protein A affinity chromatography.

Recognizes endogenous levels of Abl proteins. Species Crossreactivity: Human, mouse, rat and drosophila.